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Title
Prediction of the prognosis of advanced hepatocellular carcinoma by TERT 
promoter mutations in circulating tumor DNA
Abstract
Background & Aim
Human telomerase reverse transcriptase (TERT) promoter mutations were the 
most prevalent mutations in patients with hepatocellular carcinoma (HCC). We 
tried to detect the mutations with plasma circulating tumor DNA (ctDNA) in 
patients with advanced HCC and elucidated their clinical utility. 
Methods
ctDNA in plasma was extracted from 130 patients with advanced HCC who were 
treated with systemic chemotherapy (n=86) or transcatheter arterial 
chemoembolization (n=44), TERT promoter mutations were examined with digital 
droplet PCR. The correlations between these mutations and the clinical outcome 
of patients were analyzed.
Results
Of the 130 patients examined, 71 patients (54.6%) were positive for TERT 
promoter mutations in ctDNA, of which 64 patients were −124 bp G>A and 10 
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were −146 bp G>A. The presence of TERT promoter mutations was correlated 
with large intrahepatic tumor size (P= 0.05) and high des-gamma-
carboxyprothrombin (P= 0.005). Overall survival (OS) of the patients with the 
mutations was significantly shorter than those without them (P< 0.001), and the 
patients with high (≥1%) fractional abundance of the mutant alleles showed 
shorter survival than those with low (<1%) fractional abundance. Multivariate 
analysis revealed that the presence of TERT promoter mutation (HR: 1.94; 95% 
CI, 1.18–3.24; P< 0.01), systemic chemotherapy (HR: 2.38; 95%CI, 1.29–4.57; 
P< 0.01), and vascular invasion (HR: 2.16; 95% CI, 1.22–3.76; P< 0.01) were 
significant factors for poor OS.
Conclusions
TERT promoter mutations in ctDNA were associated with short survival and could 
be a valuable biomarker for predicting the prognosis of patients with advanced 
HCC.
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Introduction
Hepatocellular carcinoma (HCC) is one of the most common and 
deadliest cancers worldwide.1 Approximately 70%–90% of HCC develop on a 
background of chronic liver disease caused by hepatitis B virus, hepatitis C 
virus, or alcohol intake.2 Disease that is diagnosed at an advanced stage or with 
progression after locoregional therapy has a dismal prognosis.3 Systemic 
treatment is recommended in patients with well-preserved liver function (Child-
Pugh class A or B) at an advanced stage and at an intermediate stage that is 
unsuitable for locoregional treatment or transcatheter arterial 
chemoembolization (TACE).4 The introduction of new targeted agents such as 
sorafenib, lenvatinib, and regorafenib has drastically changed the systemic 
treatment against HCC.5 However, as the treatment options increase, there are 
many clinical questions, such as the timing of treatment changes and prognostic 
factors.
Hepatocarcinogenesis is a complex multistep process in which many 
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signaling cascades are altered, leading to a heterogeneous molecular profile.6 
The main mutations include those in TP53, CTNNB1, and human telomerase 
reverse transcriptase (TERT). Mutations of the TERT promoter are found in 
approximately 50% of HCC,7, 8 which are the most frequent somatic genetic 
alterations of HCC and are involved in its early stages. These mutations create 
a potential binding site for E-twenty six/ternary complex factor (TCF) 
transcription factors and increase promoter activity and TERT transcription.9 
Several clinical studies have revealed that the presence of TERT promoter 
mutations was closely correlated with poor prognosis in solid tumors such as 
lung and breast cancer.10 However, the association between these mutations 
and clinicopathological features in patients with HCC has not been well 
elucidated.
Recently, circulating tumor DNA (ctDNA) in plasma has been applied 
as a noninvasive marker for cancer diagnosis.11 ctDNA is single- or double- 
stranded DNA released by the tumor cells into the blood and thus harbors the 
mutations of the original tumor.12 Tissue biopsy is the standard diagnostic 
procedure for cancers and also provides a material for genotyping, which can 
assist in decisions regarding treatment strategies. However, it is often difficult to 
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obtain tissue clinically from HCC because most cases are hypervascular and 
the patients often show bleeding tendencies. Moreover, there are other 
problems with tissue biopsy including seeding and tumor heterogeneity. On 
these backgrounds, liquid biopsy, which is a minimally invasive procedure, is 
useful in the clinical practice of HCC.
This study was designed to estimate the clinical utility of plasma ctDNA 
for detecting TERT promoter mutations in patients with advanced HCC and to 
reveal the correlation between these mutations and prognosis.
Methods
Patients
One hundred and thirty consecutive patients with advanced HCC who 
were treated with systemic chemotherapy (sorafenib or lenvatinib) or TACE at 
Okayama University Hospital between September 2013 and September 2018 
were enrolled in this study13 (Hepatol Res. 2015; 45(2). doi: 10.1111/hepr.12464. 
Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The 
Japan Society of Hepatology 2013 Update (3rd JSH-HCC Guidelines)). All 
patients provided written informed consent for the use of their plasma in this study. 
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We investigated the detection rate of TERT promoter mutations in plasma. 
Clinical data were taken from an electronic database. This study was approved 
by our institutional review board, registered at UMIN in 2013 (UMIN000011814), 
and conducted according to the Helsinki Declaration. 
DNA isolation from plasma
In all 130 patients, plasma samples were obtained from their blood prior 
to the treatments. ctDNA was extracted from 1 ml plasma samples with QIAamp 
Circulating Nucleic Acid Kit (QIAGEN, Hilden, Germany) with the QIAvac 24 Plus 
vacuum manifold in accordance with the manufacturer’s instructions and was 
stored at −30°C until analysis. DNA concentration was evaluated with the 
NanoDrop 2000 (Thermo Fisher Scientific, Waltham, MA, USA).
Droplet digital PCR (ddPCR)
TERT promoter mutations (−124bp G>A and −146bp G>A) were 
analyzed by droplet digital PCR (ddPCR; Bio-Rad Laboratories, Hercules, CA, 
USA). 
For detection of −124bp G>A, we used an TERT expert design assay 
(Bio-Rad Laboratories, Hercules, CA, USA), which was designed to detect TERT 
promoter mutation at −124bp G>A. Five microliters of DNA from plasma was 
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added to 10 μL droplet PCR supermix (Bio-Rad Laboratories), 1 μL primer/probe 
mixture (The TERT C228T_88 Assay, Bio-Rad Laboratories), 3.5 μL sterile 
DNase-and RNase-free water, 2 μL 5 M betaine, 0.25 μL 80 mM EDTA, and 0.25 
μL CviQI enzyme. A total of 22 μL mixture was added to 70 μL droplet generator 
oil (Bio-Rad Laboratories) to generate droplets. The emulsion was thermal cycled, 
starting with enzyme activation for 10 min at 95°C, followed by 40 cycles of 30 
sec at 96°C, and 1 min at 62°C. The cycling then finished with 10 min at 98°C for 
enzyme deactivation and holding at 4°C. The rate of temperature rise was set at 
2.5°C/s. 
For the detection of −146bp G>A, we designed the primer probe set. 
The primer and probe sequences for each TaqMan assay were as follows: TERT 
forward primer, 5’-GGCCGCGGAAAGGAA-3’; TERT reverse primer, 5’-
CCCTTCACCTTCCAGCTC-3’; TERT FAM probe(G), 5’-
CCCG+G+A+AGG+GG-3’; TERT HEX probe(A). 5’-CCCG+G+G+AGGG. Two 
microliters of DNA from plasma were added to 10 μL droplet PCR supermix (Bio-
Rad Laboratories), 1 μL primer/probe mixture for FAM, 1 μL primer/probe mixture 
for HEX, and 6 μL sterile DNase-and RNase-free water. A total of 20 μL mixture 
was added to 70 μL droplet generator oil. The emulsion was thermal cycled, 
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starting with enzyme activation for 10 min at 95°C, followed by 40 cycles of 30 
secs at 94°C, and 1 min at 53°C. The cycling then finished with 10 min at 98°C 
for enzyme deactivation and holding at 4°C. The rate of temperature rise was set 
at 2.5°C/s.
When the cycling was complete, the fluorescence signal of each droplet 
was measured by QX200 Droplet Reader (Bio-Rad Laboratories) using 
QuantaSoft (Bio-Rad Laboratories). All samples were analyzed in duplicate.
Statistical methods
All statistical analyses were performed using JMP Pro 12.0.1 (SAS 
Institute, Cary, NC, USA). Baseline characteristics were summarized with 
medians and ranges. Categorical data were analyzed with χ2 test or Fisher’s 
exact test. Overall survival (OS) was calculated according to the Kaplan-Meier 
method, and Wilcoxon signed-rank test was used to compare OS among patient 
subgroups.
The following parameters were used to analyze the factors for OS: age, 
sex, viral markers (hepatitis B virus surface antigen and hepatitis C virus 
antibody), Child-Pugh class, number of tumors, intrahepatic tumor size, vascular 
invasion, UICC stage, total bilirubin, albumin, aspartate aminotransferase (AST), 
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alanine aminotransferase (ALT), platelets (PLT), prothrombin activity, α-
fetoprotein (AFP), des-gamma carboxyprothrombin (DCP), and the presence of 
TERT promoter mutations in plasma. Variables associated with OS were 
assessed by Cox proportional hazard model. Variables with P-values of < 0.05 in 
univariate comparison were subjected to multivariate analysis. P< 0.05 was 
considered statistically significant.
Results
Demographic and clinical characteristics of patients
Median age was 72 years old and 89 (68.5%) patients were male. As for 
HCC treatments, 86 (66.2%) and 44 patients (33.8%) received systemic 
chemotherapy (sorafenib and/or lenvatinib) and TACE, respectively. HCV 
antibody and HBs antigen were positive in 61 patients (46.9%) and 18 patients 
(13.8%), respectively. Median intrahepatic tumor size was 30 mm (range, 0–195 
mm), and the clinical stages of 27, 25, 35, and 41 patients were II, III, IVa, and 
IVb, respectively. The median follow-up period was 12.9 months (interquartile 
range, 7.1–24.0 months) (Table 1).
Determination of cut-off of amplitude to detect TERT promoter mutation
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The results of ddPCR were displayed as a two-dimensional histogram 
showing wild-type and mutational types. First, we defined the threshold of 
fluorescence amplitude using positive and negative control samples from the 
plasmid. According to the results, we defined an amplitude greater than 4500 as 
positive for mutational types and greater than 2500 as positive for wild-type (data 
not shown).
TERT promoter mutations in plasma
Of the 130 patients examined, 71 patients (54.6%) were positive for 
TERT promoter mutations in ctDNA, of which 64 patients were −124bp G>A and 
10 patients were −146bp G>A. Clinicopathological characteristics according to 
mutational status are shown in Table 2. The presence of TERT promoter 
mutations was correlated with large intrahepatic tumor size (P= 0.05) and high 
DCP (P= 0.005).
Relationship between TERT promoter mutations and overall survival
In this study, we analyzed the relationship between TERT promoter 
mutations and overall survival after initiation of therapy by systemic 
chemotherapy (sorafenib or lenvatinib) or TACE. We calculated and plotted 
Kaplan-Meier survival curves. The OS of the patients with these mutations was 
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significantly shorter than those without them (P< 0.001; Figure 1A). Median 
survival time was 12.8 months and 27.0 months in patients with and without TERT 
promoter mutations in plasma, respectively. The OS of the patients with the 
mutation of −124bp G>A was significantly shorter than those without it, but not 
for the mutation of −146bp G>A (Supplementary Figure 1).
The same relationship was observed when we divided the patients by 
treatments. OS of the HCC patients with TERT promoter mutations treated with 
systemic chemotherapy (median, 11.2 months) was significantly shorter than 
those without them (median, 22.2 months; P= 0.002; Figure 1B). Similarly, the 
OS of the HCC patients with TERT promoter mutations treated with TACE 
(median, 27.6 months) was significantly shorter than those without them (median, 
54.7 months; P= 0.02; Figure 1C). 
We also evaluated the fractional abundance of mutant alleles of TERT 
promoter in ctDNA among those samples with TERT promoter mutations. The 
OS of the patients who had high (≥1%) fractional abundance was significantly 
shorter than the patients who had low (<1%) fractional abundance (Figure 2).
In univariate analysis with Cox proportional hazards model, the 
presence of TERT promoter mutations (hazard ratio (HR): 2.19; 95% confidence 
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interval (CI): 1.36–3.61; P= 0.001), systemic therapy (HR: 3.30; 95%CI: 1.87–
6.14; P< 0.001), high AFP (HR: 1.85; 95%CI: 1.16–2.97; P= 0.01), high DCP (HR: 
2.01; 95%CI: 1.25–3.25; P= 0.003), metastasis (HR: 1.78; 95%CI: 1.07–2.92; P= 
0.03), and vascular invasion (HR: 3.31; 95% CI: 1.96–5.48; P= 0.001) were 
significant factors for poor OS. Multivariate analysis revealed that TERT promoter 
mutations (HR: 1.94; 95% CI: 1.18–3.24; P= 0.009), systemic chemotherapy (HR: 
2.38; 95%CI: 1.29–4.57; P= 0.006), and vascular invasion (HR: 2.16; 95% CI: 
1.22–3.76; P= 0.009) were significant factors for poor OS (Table 3).
We further evaluated the effect of HCV and HBV infection on the 
relationship between TERT promoter mutations in plasma ctDNA and the 
prognosis of patients. The OS of the HCC patients with HCV and the mutations 
was significantly shorter than those without the mutations (P< 0.001; Figure 3A). 
Median survival time was 12.8 months and 34.7 months, respectively. However, 
no difference in OS was observed in HCC patients with and without TERT 
promoter mutations in cases of HBV infection (P= 0.77; Figure 3B). The OS of 
the HCC patients with NBNC and the mutations was significantly shorter than 
those without the mutations (P= 0.02; Supplementary Figure 2).
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Discussion
Somatic mutations in the transcriptional regulatory region of the TERT 
gene have been reported in a range of cancers, including HCC. In this study, we 
analyzed the ctDNA of 130 HCC patients who were treated with systemic 
chemotherapy (sorafenib or lenvatinib) or TACE. We detected TERT promoter 
mutations in 71 cases of the 130 cases analyzed (54.6%) by ddPCR, which was 
similar to the previously reported prevalence (44.4%–65%).7, 8, 14 The prevalence 
of the mutations located 124 bp and 146 bp upstream of the ATG start site were 
49.2% and 7.8%, respectively. Furthermore, we demonstrated that the TERT 
promoter mutations in ctDNA were closely correlated with a poor prognosis in 
OS, especially in patients with HCV infection.
Telomerases are responsible for the maintenance of chromosomal 
integrity and genome stability. Telomerase activity is inactivated during gestation 
and thereafter is reactivated in 90% of human cancer cells, including HCC.15, 16 
There are two mechanisms of reactivation of TERT activity: (a) through epigenetic 
regulation and (b) through somatic mutations in the TERT promoter, which has 
been recently discovered in other solid tumors.17 Knowing that telomeres are 
necessary for cellular self-renewal, the mechanisms responsible for telomere 
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maintenance have a crucial role in cancer development and might be important 
oncological biomarkers.9 Wang et al.10 reported that overexpression of TERT was 
associated with poor survival in human solid tumors, such as lung cancer, 
glioblastoma, and breast cancer, and our results showed a similar trend in HCC. 
TERT promoter mutations have two hot spots: −124bpG>A and −146bp G>A. In 
this study, we demonstrated that the OS of the patients with the mutation of 
−124bp G>A was significantly shorter than those without it, but not for the 
mutation of −146bp G>A. However, we speculated that −146bp G>A has the 
same effect as −124bp G>A because previous research showed that both 
mutations are functionally active.9 However, this result may be due to the small 
number of mutated samples with −146bp G>A.
The detection of TERT promoter mutations in plasma may reflect an 
abundance of immortal and rapidly proliferating cells in HCC, which might result 
in poor prognosis. It is difficult to evaluate the whole tumor information by tissue 
biopsy, because the amount of tissue biopsy is limited despite the presence of 
tumor heterogeneity. Differing from tissue biopsy, liquid biopsy might have 
another potential: ctDNA can be a representative of the genome at the poorest 
differentiation site in the tumor. We have already clarified the usefulness of liquid 
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biopsy in patients with pancreatic, gastric, and gallbladder cancer, not only for 
prediction of prognosis but also for detection of the cancers.18-20 These results 
support the results of the current study with HCC.
The frequency of the mutations was higher in HCV-positive cases 
(35/61; 57%) than those in HBV-positive cases (9/18; 50%). This is the almost 
same result as previous reports,21 although there was no statistically significant 
difference in our study. Moreover, we demonstrated that TERT promoter 
mutations were associated with poor prognosis in HCV-related HCC but not HBV-
related HCC. The most likely explanation is that HBV-associated HCCs involve 
other mechanisms of maintaining telomere integrit.22 It has been reported that the 
TERT promoter is one of the most frequent integration sites for the HBV genome 
in HCC. Inserting a viral genome causes the juxtaposition of viral enhancers to 
be near the TERT gene and the potential activation of TERT expression.23 Kawai-
Kitahara8 et al reported that HBV integration into the TERT locus was found in 
47% HBV-related HCC cases who were negative for TERT promoter mutations 
and most (89%) HBV integrants were in the HBx region, which was known to 
have effects on the transcriptional levels of many genes.
We also showed in this study that the patients who had a higher 
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fractional abundance of TERT promoters in ctDNA had a poorer prognosis in the 
patients with TERT promoter mutations. The rapid turnover of cancer cells may 
have caused this result. This appears to further emphasize on that TERT 
mutations are associated with prognosis. However, there are few reports 
describing the fractional abundance of TERT promoter mutations and further 
research is needed.
This study has some limitations. First, this is a retrospective cohort and 
a single-center study. Prospective and multiple center studies are warranted for 
further verification in other patient populations. Second, we only focused on TERT 
promoter mutations. Combined analysis of other mutated genes such as TP53 
and CTNNB1 might result in precise prognosis prediction. Another limitation is 
the difficulties in determining the origin of the TERT promoter mutations in plasma. 
This is a universal weak point of liquid biopsy. We performed a previous study to 
elucidate the positivity between tissue and plasma or serum of HCC patients who 
had surgical resection, but more strong evidence might be made, if sampling 
tissue from patients who had systemic therapy prior to the treatment.
In conclusion, TERT promoter mutations in ctDNA were associated with 
poor prognosis and could be a good target for liquid biopsy. Further research is 
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needed to confirm the clinical usefulness of TERT promoter mutations and of 
other mutations that lead to more accurate prediction of prognosis as well as 
aiding selection of treatment strategies.
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  Male 89 (68.5)
  Female 41 (31.5)
Age, year 72 (42-88)
Treatment, n (%)
  Systemic chemotherapy 86 (66.2)
  TACE 44 (33.8)
Etiology, n (%)
  HBV 18 (13.8)
  HCV 61 (46.9)
  Alcohol 18 (13.8)
  Others or Unknown 33 (25.4)
Total bilirubin, mg/dL 0.8 (0.3-3.0)
Albumin, g/dL 3.5 (2.3-4.5)
Aspartate aminotransferase, IU/L 37 (16-510)
Alanine aminotransferase, IU/L 27.5 (6-142)
Platelet, ×103/mm3 120 (21-414)
Prothrombin activity, % 91.5 (23-127)
Tumor number, n (%)
  0-1 41 (31.5)
  ≥2 89 (68.5)
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Intrahepatic tumor size, mm 30 (0-195)
Child-Pugh class, n (%)
  A 100 (76.9)
  B 30 (23.1)
Tumor marker
  AFP, ng/ml 29.8 (1.2-415825)
  Des-gamma carboxyprothrombin, mAU/ml 240 (10-926400)
Tumor stage, n (%)†
  Ⅱ 27 (21.1)
  Ⅲ 25 (19.5)
  Ⅳa 35 (27.3)
  Ⅳb 41 (32.0)
Vp, n (%)
  0 101 (77.7)
  1 9 (6.9)
  2 12 (9.2)
  3 5 (3.8)
  4 3 (2.3)
Follow-up duration, day 385.5 (31-2124)
hTERT promoter mutation (ctDNA), n (%) 71 (54.6)
 -124bp G>A 64 (49.2)
 -146bp G>A 10 (7.8)
† Two cases had no data available. Values are indicated as median (range) unless 
otherwise noted.
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Table 2. Demographic clinical variables in 130 patients with HCC by TERT promoter 
mutations in ctDNA





Patients, n (%) 71 (54.6) 59 (45.4)
Gender, n (%) 0.54
  Male 47 (66.2) 42 (71.2)
  Female 24 (33.8) 17 (28.8)
Treatment, n (%) 0.99
  Systemic chemotherapy 47 (66.2) 39 (66.1)
  TACE 24 (33.8) 20 (33.9)
Median Age (range), year 73 (36-88) 71 (42-88) 0.29
PS, n (%) 0.25
  0 50 (70.4) 48 (81.4)
  1 19 (26.8) 9 (15.3)
  2 2 (3.4) 2 (2.8)
Etiology, n (%) 0.08
  HBV 9 (12.7) 9 (15.3) 0.67
  HCV 35 (49.3) 26 (44.1) 0.55
  Alcohol 13 (18.3) 5 (8.5) 0.11
  Others or Unknown 14 (19.7) 19 (32.2) 0.34
Median total bilirubin (range), mg/dL 0.9 (0.31-2.99) 0.74 (0.31-1.82) 0.09
Median Albumin (range), g/dL 3.5 (2.5-4.5) 3.6 (2.3-4.4) 0.49
Median Aspartate aminotransferase (range), 
IU/L
41 (17-510) 35 (16-213) 0.22
Median Alanine aminotransferase (range), 
IU/L
28 (9-121) 26 (6-142) 0.29
Median Platelet (range), ×103/mm3 115 (35-414) 126 (21-297) 0.95
Median Prothrombin activity (range), (%) 92 (23-127) 91 (23-124) 0.56
Tumor number, n (%) 0.10
  0-1 18 (25.4) 23 (39.0)
  ≥2 53 (74.7) 36 (61.0)
Median intrahepatic tumor size (range), mm 33 (0-128) 23 (0-195) 0.05
Child-Pugh class, n (%) 0.80
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  A 54 (76.1) 46 (78.0)
  B 17 (22.9) 13 (22.0)
Tumor marker
  Median AFP (range), ng/ml 75.7 (1.4-415825) 17.1 (1.2-17859) 0.07
  Median Des-gamma carboxyprothrombin 
(range), mAU/ml
417 (10-650210) 163 (10-926400) < 0.01
Tumor stage, n (%) 0.63
  Ⅱ 10 (14.1) 17 (29.8)
  Ⅲ 18 (25.4) 7 (12.3)
  Ⅳa 23 (32.4) 12 (21.1)
  Ⅳb 20 (28.2) 21 (36.8)
Vp, n (%) 0.34
  0 52 (73.2) 49 (83.1)
  1 6 (8.5) 3 (5.1)
  2 8 (11.3) 4 (6.8)
  3 4 (5.6) 1 (1.7)
  4 1 (1.4) 2 (3.4)
Values are indicated as median (range) unless otherwise noted.
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Table 3. Predictors of overall survival for patients with advanced HCC
Univariate analysis Multivariate analysisVariables
HR (95%CI) p-value HR (95%CI) p-value
With hTERT promoter mutation
(-124bp G>A or -146bp G>A)
2.19 (1.36-3.61) < 0.01 1.94 (1.18-3.24) < 0.01
With hTERT promoter mutation
(-124bp G>A)
2.55 (1.59-4.15) < 0.01
With hTERT promoter mutation
(-146bp G>A)
0.87 (0.30-1.96) 0.76
Age (≥72 yr.) 1.30 (0.81-2.08) 0.28
Male 0.87 (0.54-1.44) 0.58
Systemic chemotherapy (vs TACE) 3.30 (1.87-6.14) < 0.01 2.38(1.29-4.57) < 0.01
PS (≥1) 0.69 (0.37-1.19) 0.18
HBV (Positive) 1.96 (0.99-3.55) 0.05
HCV (Positive) 0.81 (0.50-1.28) 0.36
Total bilirubin (≥0.8 mg/dL) 1.48 (0.93-2.38) 0.1
Albumin (<3.5 g/dL) 1.58(0.99-2.52) 0.05
Aspartate aminotransferase (≥37 IU/L) 1.34 (0.84-2.15) 0.22
Alanine aminotransferase (≥27.5 IU/L) 0.85 (0.53-1.37) 0.51
Platelet (≥120 ×103/mm3) 1.50 (0.94-2.41) 0.09
Prothrombin activity (≥91.5%) 1.0 (0.62-1.59) 0.99
Number of tumors ≥2 (vs 0-1) 1.51 (0.91-2.58) 0.11
intrahepatic tumor size (≥30mm) 1.10 (0.69-1.78) 0.68
Child-Pugh class B (vs A) 1.30 (0.75-2.15) 0.33
AFP (≥29.75) 1.85 (1.16-2.97) 0.01 1.20 (0.71-2.03) 0.49
Des-gamma carboxyprothrombin (≥240) 2.01 (1.25-3.25) 0.003 1.62 (0.98-2.71) 0.06
With metastasis 1.78 (1.07-2.92) 0.03 1.34 (0.77-2.33) 0.30
Vascular invasion (Positive) 3.31 (1.96-5.48) < 0.01 2.16 (1.22-3.76) < 0.01
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Figure Legends
Figure 1 
Overall survival (OS) curves according to TERT promoter mutational status 
evaluated by the Kaplan-Meier method. OS of HCC patients with TERT promoter 
mutations was significantly shorter than the patients without the mutations (P< 
0.01) (a). The same relationship was observed in patients treated with systemic 
chemotherapy (P< 0.01) (b) and TACE (P= 0.02) (c).
Figure 2
Effect of fractional abundance of mutant alleles of TERT promoter. OS was 
significantly shorter in patients with high allele frequency than those with low 
allele frequency (P< 0.01).
Figure 3
Effect of TERT promoter mutational status in HCC patients with different viral 
infections. TERT promoter mutations were associated with poor prognosis in (a) 
HCV-related HCC patients (P<0.01) but not in (b) HBV-related patients (P= 0.77). 
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Supplementary Figure 1.
The overall survival curves according to the telomerase reverse transcriptase 
promoter mutation status of -124bp G>A (A)and -146bp G>A (B).
Supplementary Figure 2
The overall survival of the patients with NBNC-HCC according to the telomerase 
reverse transcriptase promoter mutation status.
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